NextCell Pharma publish Interim Report 1 2024/2025

January 30, 2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2024 – November 30, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

First Quarter (2024-09-01 to 2024-11-30)

Operating income amounted to 2,864 (4,695) TSEK, of which Cellaviva contributed 2,828 (4,246) TSEK.
Net sales amounted to 2,828 (4,246) TSEK.
Profit/loss after financial items amounted to -8,042 (-9,796) TSEK.
Earnings per share* were -0.11 (-0.28) SEK.
Cash and cash equivalents amounted to 34,123 (40,428) TSEK.
Equity ratio** amounted to 86 (81) percent.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the first quarter of 2024/2025: 73,091,327 (34,379,523) shares. The number of shares in NextCell as of 30 November 2024: 73,091,327 (34,379,523) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the first quarter

At the beginning of September, the Company presented new clinical long-term data at the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting. The results demonstrate the long-term safety and efficacy of the treatment in preserving endogenous insulin production, along with additional health benefits for patients with type 1 diabetes (T1D), such as lower BMI and blood pressure.
At the end of September, the Company announced that the first four children in the 7–11 age group had been treated in the latest phase of the ProTrans-Young study, with an additional four children screened and expected to begin treatment shortly. These developments mark a significant milestone in the study, which is progressing faster than anticipated.
In early October, the Company announced that ProTrans was highlighted as a promising treatment for type 1 diabetes in Dagens Medicin.
In early November, NextCell Pharma participated in BIO-Europe 2024, one of Europe’s most important partnering conferences in biotechnology and pharmaceutical development, which was attended by Sweden's Minister for Energy and Enterprise and Deputy Prime Minister, Ebba Busch.
At the end of November, QVance, a subsidiary of NextCell Pharma, announced two significant partnerships with bioMérieux Sweden and Royal International.
In late November, the Company announced that Eva Sjökvist Saers was elected as a new board member at the Annual General Meeting.

Significant events after the reporting period

In December, NextCell reported new results from the ProTrans-Repeat study. "The results from the ProTrans-Repeat study are very encouraging and show that repeated treatment can preserve and even improve insulin production over six years. This strengthens ProTrans' potential as a safe and effective treatment for modifying the progression of type 1 diabetes," commented Mathias Svahn, CEO.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on
30th January 2025, 08.30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: 0+46 8-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

For information about Cellaviva, please contact:

Sofie Falk Jansson, CEO

Tel: 08-735 2010

E-mail: info@cellaviva.se

Website: www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige

Twitter: https://www.instagram.com/cellaviva/

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser

About NextCell Pharma AB

NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.

Download attachment Read full press release on Cision (external link)

2019-12-11

Extended permission from the Medical Products Agency

NextCell Pharma AB ("NextCell") announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a regular inspection by the Medical Products Agency which resulted in the wholesale distribution authorization being extended for five years. The wholesale distribution authorization allows NextCell to store and distribute the study drug, ProTrans, for use in the clinical trials. In addition to the Medical Products Agency, the Health and Care Inspectorate (IVO) acts as supervisory

Read more Read more

2019-12-04

Promising Results from clinical trial with ProTrans stem cells

NextCell Pharma AB ("NextCell") announces today that the primary efficacy measures have reached significance in the dose-escalation phase of the company’s clinical trial. After one year follow-up, the six patients treated with high- and medium-dose have retained their insulin production significantly better (P <0.01) as compared to the three patients who received a low-dose of the company's stem cell based drug candidate ProTrans. No serious side effects have been reported. "The results very are promising, even though there are only few patients and this part of the clinical trial was an

Read more Read more

2019-11-22

A part of Vision-driven Health

NextCell Pharma AB ("NextCell") announces that it is chosen as one of the collaborators in the newly Vinnova funded project Vision-driven Health: Sweden a leader in advanced therapies in 2030. Vinnova is investing in establishing five vision-driven innovation environments to meet important health challenges. These include zero vision for malnutrition in the elderly, elimination of cancer as a cause of death and counteracting antibiotic resistance. NextCell is participating in one of the approved five projects: Sweden a leader in advanced therapies in 2030. This project which is

Read more Read more

2019-11-07

Correction: Notice to attend the Annual General Meeting

NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. Compared to the press release published this morning, corrections have been made regarding the Market Abuse Regulation label. The information is not subject to the Market Abuse Regulation. The annual general meeting will be held on December 5, 2019 at 10.00 at Novum, Hälsovägen 7, Huddinge. The notice has been published in Svenska Dagbladet and Post and Inrikes Tidningar as well as on the company's website, www.nextcellpharma.com. The Annual Report and

Read more Read more

2019-11-07

Notice to attend the Annual General Meeting

NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. The annual general meeting will be held on December 5, 2019 at 10.00 at Novum, Hälsovägen 7, Huddinge. The notice has been published in Svenska Dagbladet and Post and Inrikes Tidningar as well as on the company's website, www.nextcellpharma.com. The Annual Report and Audit Report will be available three weeks before the Meeting, November 14, on the Company's website, www.nextcellpharma.com. This information is the information that NextCell Pharma AB

Read more Read more

2019-10-31

Year-end report 2018-09-01 - 2019-08-31

Nextcell Pharma AB ("NXTCL") today announces the year-end report for the 2018/2019 fiscal year (2018-08-31 2019-08-31) Twelve months (2018-09-01 until 2019-08-31) · Operating income amounted to SEK 1 964 132 (655 413). · Operating result amounted to SEK -21 450 784 (-14 032 294). · Earnings per share* amounted to SEK -1.36 (-0.61). · Cash and bank amounted to SEK 20 128 185 (3 115 876). · Solidity** amounted to 85.9 (59.2) %. Fourth quarter (2019-06-01 until 2019-08-31) · Operating income amounted to SEK 551 708 (127 868). · Operating result

Read more Read more

2019-10-25

NextCell invests in the Danish Cellaviva operations with a new Copenhagen office

NextCell Pharma AB ("NextCell") today announces they are investing for growth in Cellaviva's Danish operations with the opening of a new Copenhagen office. In October, Cellaviva's new office was opened in Copenhagen, located in Kløvebyen. The Copenhagen office is primarily intended to be a hub for the Danish Cellaviva business with the opportunity to host customers, hold training sessions etc. The purpose is also to enable increased exposure and presence for NextCell in the Öresund region. [image] [image]

Read more Read more

2019-10-01

All patients in ProTrans-Repeat are now treated

NextCell Pharma AB ("NextCell") announces that another significant milestone has been reached when the last patient, as part of the ProTrans-Repeat active treatment group, today has received their treatment. This implies that all treatments, related to the two ongoing ProTrans studies, have been completed. NextCell is conducting two parallel clinical trials with the drug candidate ProTrans, with the aim to treat diabetes type-1. ProTrans-Repeat, which was initiated in May 2019, is a continuation trial of ProTrans-1 dose escalation part with the aim of maximizing data collection on repeated

Read more Read more